GHK-Cu vs Adrenomedullin
Side-by-Side Comparison
| Attribute | Ghk Cu | Adrenomedullin |
|---|---|---|
| Category | Skin & Tissue Repair | Cardiovascular / Vasoactive |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. | Adrenomedullin signals through the calcitonin receptor-like receptor (CLR) complexed with receptor activity-modifying protein 2 or 3 (RAMP2/RAMP3), forming the AM1 and AM2 receptors respectively. |
| Evidence Rating | F — No Regulatory Activity | D — Biomarker / Early Research |
| Clinical Status | Available in cosmetic formulations; no drug approval | Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide. |
| Safety Profile | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin | No human safety data from controlled therapeutic trials; Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia |
| Route | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) | Intravenous infusion (research only) |
| Dose Range | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area | 10–50 ng/kg/min in human physiological studies |
| Frequency | SC: Once daily; Topical: 1–2x daily | Continuous or bolus infusion |
| Molecular Weight | ~403.9 g/mol | ~6028 g/mol |
| Half-Life | ~30 minutes plasma | ~22 minutes (plasma) |
Overview
GHK-Cu and Adrenomedullin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Adrenomedullin — Mechanism & Evidence
Adrenomedullin is a 52-amino-acid vasodilatory peptide (MW ~6028 g/mol) originally isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, with potent vasodilatory, natriuretic, and cardioprotective properties. It is currently investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis, with no approved therapeutic use of the peptide itself.
Key claims: MR-proADM is a strong prognostic biomarker in sepsis; MR-proADM predicts mortality in acute heart failure; Adrenomedullin has potent vasodilatory effects in humans.
Shared Research Applications
These peptides target different research areas. GHK-Cu focuses on Skin Health, Anti-Aging, Wound Healing, while Adrenomedullin targets Sepsis Prognostication, Heart Failure Biomarker, Cardiovascular Research.
Safety Considerations
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Adrenomedullin: No human safety data from controlled therapeutic trials Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia Theoretical risk of excessive vasodilation and hemodynamic instability
Related Products
Related Research News
GHK-Cu: Copper Peptide in Tissue Repair and Skin Research
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, stands out as a naturally occurring peptide central to human tissue maintenance and repair. Found in plasma, saliva, urine, and skin, its levels drop from about 200 ng/mL in young adults with age, linking to reduced regeneration. Preclinical studies highlight its roles in collagen production, wound healing, angiogenesis, anti-inflammation, and more, with the copper complex showing greater potency than unbound GHK.
Glow Blend: GHK-Cu, BPC-157 & TB-500 Peptide Research
Glow Blend combines GHK-Cu, BPC-157, and TB-500 in a 70mg multi-peptide formulation studied for skin biology, tissue repair, and cellular processes. Each component targets overlapping areas like collagen pathways, connective tissue response, and cell migration. This guide explains their research roles, molecular details, and why they pair together in regenerative studies.
BPC-157 vs GHK-Cu: Comparing Top Research Peptides
BPC-157 and GHK-Cu stand out among research peptides for their extensive studies in tissue repair and anti-aging. BPC-157, a 15-amino-acid peptide from human gastric juice, focuses on angiogenesis and wound healing. GHK-Cu, a copper-bound tripeptide from human plasma, targets gene expression and skin remodeling, with over 100 published studies.